Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 12/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491795 | 0.87 | RXFP1 (0.88) | RXFP1MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15530136 | 0.83 | RXFP1 (0.70) | RXFP1MAPT | |
| SCHEMBL15528441 | 0.81 | RXFP1 (0.79) | RXFP1MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15528928 | 0.81 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL15528979 | 0.81 | RXFP1 (0.78) | RXFP1MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL27497023 | 0.79 | RXFP1 (0.60) | RXFP1MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15529016 | 0.78 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL15528909 | 0.78 | RXFP1 (1.00) | RXFP1 | |
| SCHEMBL15530591 | 0.77 | RXFP1 (0.72) | RXFP1MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15530589 | 0.77 | RXFP1 (1.00) | RXFP1MAPTCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844345-B1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | US HEALTH (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| EP-2844345-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013165606-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | RXFP1 1/4885MAPT 4541/4885CYP1A2 1924/4885 |
| US-10125112-B2 | Modulators of the relaxin receptor 1 | RXFP1, RXFP2, RXFP3 | RXFP1 1/4885MAPT 4541/4885CYP1A2 1924/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | RXFP1 1/4885MAPT 4541/4885CYP1A2 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.